Prior to this year’s Annual Meeting of the American Association for Cancer Research (AACR), it had been 14 years since metastasis had been the subject of a plenary session. So, the Tuesday session on “Evolution of the genome, microenvironment, and host through metastasis” had plenty of new insights to share.
Prior to this year’s Annual Meeting of the American Association for Cancer Research (AACR), it had been 14 years since metastasis had been the subject of a plenary session. So, the Tuesday session on “Evolution of the genome, microenvironment, and host through metastasis” had plenty of new insights to share.
Everzom SAS, a CNRS/Université Paris Cité spin-off, has signed a second exclusive license agreement with Erganeo SAS for the development of Evergel, an exosome drug candidate for fistulas and fibrosis of the digestive tract.
There is increasing interest in studying exosome molecules, and particularly long non-coding RNAs (lncRNAs), in the diagnosis of gastric cancer. Microarray analysis was performed from samples obtained from patients with gastric cancer who underwent endoscopic resection.
Nurexone Biologic Inc. has completed a pre-IND meeting with the FDA in connection with the manufacturing, preclinical and clinical development plan of Exopten. Exopten is being developed to be a minimally invasive Exotherapy product for spinal cord injuries given intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords.
Nurexone Biologic Inc. is developing Exopten as a minimally invasive Exotherapy for spinal cord injuries (SCI). The company's platform produces and loads exosomes with pharmaceutical cargo, targeting SCI intranasally in the case of lead product Exopten.